Cargando…
How splicing confers treatment resistance in prostate cancer
A splice variant of the androgen receptor that drives prostate cancer resistance translocates into the nucleus using a different mechanism from the full-length receptor and exhibits distinct molecular properties once inside.
Autores principales: | Konda, Prathyusha, Viswanathan, Srinivas R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398401/ https://www.ncbi.nlm.nih.gov/pubmed/35998026 http://dx.doi.org/10.7554/eLife.82070 |
Ejemplares similares
-
Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
por: Sun, Rui, et al.
Publicado: (2023) -
TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth
por: Palit, Sander AL, et al.
Publicado: (2019) -
Overexpression of claspin promotes docetaxel resistance and is associated with prostate‐specific antigen recurrence in prostate cancer
por: Babasaki, Takashi, et al.
Publicado: (2021) -
Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
por: Wu, Meng, et al.
Publicado: (2023) -
Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer
por: Shah, Neel, et al.
Publicado: (2017)